U.S., July 19 -- ClinicalTrials.gov registry received information related to the study (NCT07072195) titled 'A Phase 2 Clinical Trial Evaluating the Safety and Efficacy of AMC6156 in People With Sarcopenia' on July 09.
Brief Summary: This clinical trial aims to find out whether AMC6156 can improve physical function and is safe in older adults with sarcopenia. Participants will take AMC6156 or a placebo daily for 12 weeks, and their movement, strength, and safety will be regularly monitored through tests and checkups.
Study Start Date: July 01
Study Type: INTERVENTIONAL
Condition:
Sarcopenia in Elderly
Sarcopenia
Intervention:
DRUG: AMC6156 0.1mg
Oral administration of AMC6156 in tablet form at a dose of 0.1 mg once daily for 12 week...